Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Patent
1995-06-07
2000-11-07
Saucier, Sandra E.
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
435238, A01N 102, C12N 706
Patent
active
061434906
ABSTRACT:
Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
REFERENCES:
patent: 3819270 (1974-06-01), Hirschfeld
patent: 4107182 (1978-08-01), Liebman et al.
patent: 4124598 (1978-11-01), Hearst et al.
patent: 4147703 (1979-04-01), Liebman et al.
patent: 4150042 (1979-04-01), Liebman et al.
patent: 4182750 (1980-01-01), Sullivan et al.
patent: 4196281 (1980-04-01), Hearst et al.
patent: 4252653 (1981-02-01), Beck et al.
patent: 4269851 (1981-05-01), Kaufman
patent: 4269852 (1981-05-01), Kaufman
patent: 4294822 (1981-10-01), Kaufman
patent: 4298614 (1981-11-01), Kaufman
patent: 4370344 (1983-01-01), Kaufman
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 4748120 (1988-05-01), Wiesehahn
patent: 4970230 (1990-11-01), Goupil
patent: 5055485 (1991-10-01), Geacintov et al.
patent: 5399719 (1995-03-01), Wollowitz et al.
patent: 5473083 (1995-12-01), Heindel et al.
Heaton et al., British J. Haematology 57(3):467-78 (1984).
Shooter et al., "Assays for phosphotriester formation in the reaction of bacteriophage R17 with a group of alkylating agents", Chemico-Biological Interactions 11 (6) : 575-88 (1975).
Lawley et al., "Inactivation of bacteriophage T7 by mono-and difunctional sulfur mustards in relation of cross-linking and depurination of bacteriophage DNA", J. Molecular Biology 39 (1) : 181-98 (1969).
Rytir et al. (1974). "A study on the effect of certain compounds during elimination of plasmids in Escherichia coli" Folia Microbiol. 20:17-23.
Resnick, et al., Human T-cell lymphotrophic viruses: Synctia Formation, JAMA 255:1887 (1986).
Update: HIV Infections in health-care workers exposed to blood of infected patients; Morbidity and Mortality Weekly Report 36:285 (1987).
Dodd, R.Y. "Will Blood Products be free of infectious agents?" Transfusion Medicine in the 1990's American Association Blood Banks (1990).
Surgenor, D.M. et al., Red cell transfusions in coronary artery bypass surgery (DRFs 106 and 107), Transfusion 32:458-464 (1992).
Wallace, E.L., et al, "Collection and transfusion of blood and blood components in the United States, 1989", Transfusion 33:139-144 (1993).
"How Safe Is Our Blood", U.S. News and World Report, Jun. 27, 1994, 68-78.
Hilfenhaus, J., et al., "A strategy for testing established human plasma protein manufacturing procedures for the ability to inactivate or eliminate human immunodeficiency virus" J. Bio. Stand 15:251-263 (1987).
Horowitz, B., et al., "Inactivation of viruses in labile blood derivatives" Transfusion 25:516-522 (1985).
Moroff, G., et al, "The influence of irradiation on stored platelets" Transufion 25:453-456 (1986).
Proudouz, K.N., et al., "Use of Laser-UV for inactivation of virus in blood products", Blood vol. 70:2 pp. 589-592, (1987).
Wagner, S.J., et al., "Red cell alterations associated with virucidal methylene blue phototreatment", Transfusion 33:30-36 (1993).
Bruisten, S.M., et al., "Efficiency of white cell filtration and a freeze-thaw procedure for removal of HIV-infected cells from blood", Transfusion 30:833 (1990).
Winslow, R.M., "Red cell substitutes: Current status, 1992" Nance, S.M., editor, Blood Safety: Current Challenges AABB p. 151-167 (1992).
Peck, R.M. et al., "Nitrogen mustard analogs of antimalarial drugs", J. Am. Chem. Soc. 81 3984-9 (1959).
Gravitt, G.L., et al., "DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards" J. Med. Chem 34:1552-1560 (1991).
Cummings, J., et al., "Determination of reactive nitrogen mustard anti-cancer drugs in plasma by high-performance liquid chromatography using derivatization", Anal. Chem. 63:1514 (1991).
Maron, D.M., et al., "Revised methods for the salmonella mutagenicity test" Mutation Research 113:173-215 (1983).
Lin, L., et al., "Use of 8-Metboxypsoralen and long-wavelength ultraviolet radiation for decontamination of platelet concentrates" Blood 74:1 pp. 517-525 (1989).
Ganem, D., et al., "The molecular biology of the Hepatitis B viruses" Ann. Rev. Biochem. 56:651-93 (1987).
Hanson, C.V., et al, "Application of a Rapid microplaque assay for determination of HIV neutralizing antibody titers", J. Clin. Microbio. 28:9 pp. 2030-2034 (1990).
Preston, R.K. et al., "Further investigations of heterocyclic alkylating agents", J.Med. Chem. 7:471-80 (1964).
Wilson, W.R. et al., Patent No. WO 94/27954 "Nitrobenzyl Mustard Quaternary Salts and their use as Hypoxia-selective cytotoxic agents", Filing date May 24, 1994.
LoGrippo, G.A. et al., "Chemical and combined methods for plasma sterilization", 6th Congress of the International Society of Blood Transfusion; Hollander, editor pp. 225-230 (1958).
Mattes, W.B., et al., "GC-rich regions in genomes as target for DNA alkylation", Carcinogenesis vol. 9 No. 11 pp. 2065-2072 (1988).
Prakash A.S., et al. DNA-directed alkylating ligands as potential antitumor agents: sequence specificity of alkylation by intercalating aniline mustards. Biochem. (1990);29:9799-9807.
Ferguson L.R., et al. Modulation of mutagenic properties in a series of DNA-directed alkylating agents by variation of chain length and alkylator reactivity. Mutation Res. (1992);265:181-193.
Hartley J.A., et al. Effect of ionic strength and cationic DNA affinity binders on the DNA sequence selective alkylation of guanine N7-positions by nitrogen mustards. Biochem. (1990);29:2985-2991.
Gourdie T.A., et al. Synthesis and evaluation of DNA-targeted spatially separated bis(aniline mustards) as potential alkylating agents with enhanced DNA cross-linking capability. J. Med. Chem (1991);34:240-248.
Valu K.K., et al. DNA-directed alkylating agents. 3. structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. J. Med. Chem. (1990);33:3014-3019.
Gourdie T.A., et al. DNA-directed alkylating agents. 1. structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. J. Med. Chem (1990);33:1177-1186.
Panthananickal A., et al. Structure-activity relationships in antitumor aniline mustards. J. of Med. Chem. (1978);21(1):16-26.
Sunters A., et al. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[BIS(2-chloroethyl)amino] benzoic acid. Biochem. (1992);44(1):59-64.
Fraser M.J., et al. Inactivation of bacteriophage and DNA by nitrogen mustard. Mut. Res. (1982);96;153-165.
Fox M., et al. The genetic toxicology of nitrogen and sulphur mustard. Mut. Res. (1980);75:131-168.
Millard J.T., et al. Diepoxybutane cross-links DNA at 5'-GNC sequences. Biochem. (1993);32:2120-2124.
Charache S., et al. Evaluation of extracorporeal alkylation of red cells as a potential treatment for sickle cell anemia. Blood (1976);47(3):481-488.
Antonello C., et al. Diethylaminoalkyloxycoumarin and Furocoumarin Derivatives. Il Farmaco--Ed. Sc. (1979); 34:139-156.
Friedman et al., "Viral inactivation and reduction in cellular blood products" Rev. Fr. Transfus. Hemobiol. (1993) 36: 83-91.
Krowicki, K. et al., "Novel DNA groove binding alkyiators: design synthesis, and biological evaluation" J. Med. Chem. (1988) 31:341-345.
Wagner, S.J. et al. "Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma" Transfusion Medicine Reviews (1991) 5 (1): 18-32.
Budowsky et al., "Principles of selective inactivation of the viral genome: Dependence of the rate of viral RNA modification on the number of protonizable groups in ethyleneimine oligomers" Vaccine Res. (1996) 5:29-39.
Cates et al., "Phosphorus-nitrogen compounds. 24. Phosphoramide mu
Cook David
Nerio Aileen
Wollowitz Susan
Cerus Corporation
Saucier Sandra E.
LandOfFree
Treating blood or blood product with a compound having a mustard does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating blood or blood product with a compound having a mustard, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating blood or blood product with a compound having a mustard will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1639131